Overview of UC, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current treatment options. Annualized UC therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2012 to 2022. Key topics covered include strategic competitor assessment, market characterization, unmet needs, and implications for the UC therapeutics markets.

1. PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market
Analysis to 2022
Published on 1st Feb 2014
During the forecast period from 20122022, the growth of the UC market will be driven largely by the
entry of Johnson & Johnsons (J&Js) Simponi and Takedas Entyvio, which will lead to an increase in the
overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada.
Benefits of Report: Develop and design in-licensing and out-licensing strategies through a review of pipeline
products and technologies, and by identifying the companies with the most robust pipeline.
Additionally a list of acquisition targets included in the pipeline product company list.
 Develop business strategies by understanding the trends shaping and driving the global UC
therapeutics markets.
 Drive revenues by understanding the key trends, innovative products and technologies, market
segments, and companies likely to impact the global UC therapeutics markets in the future.
 Formulate effective sales and marketing strategies by understanding the competitive landscape
and by analyzing the performance of various competitors.
 Identify emerging players with potentially strong product portfolios and create effective
counter-strategies to gain a competitive advantage.
Table of Content:Table 1: Ulcerative Colitis: Key Metrics in the 10 Major Pharmaceutical Markets, 20122022 16
Table 2: Genetic Factors That Confer a Predisposition to UC 30
Table 3: Typical Symptoms of UC 32
Table 4: Strongest Putative Risk Factors for UC 36
Table 5: Prevalence of UC in the US 41
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/

2. Table 6: Incidence of UC in the 5EU 42
Table 7: Prevalence of UC in the 5EU 43
Table 8: 10MM, Sources of UC Incidence Data Used in the Epidemiological Forecast 50
Table 9: 10MM, Sources of UC Prevalence Data Used in the Epidemiological Forecast 51
Table 10: 10MM, Incident Cases of UC, Ages =10 Years, Both Sexes, N, Select Years, 20122022 65
Table 11: 10MM, Incident Cases of UC, By Age, Both Sexes, N (Row %), 2012 67
Table 12: 10MM, Incident Cases of UC, By Sex, Ages =10 Years, N (Row %), 2012 69
Table 13: 10MM, Prevalent Cases of UC, Ages =10 Years, Both Sexes, N, Select Years, 20122022 72
Table 14: 10MM, Prevalent Cases of UC, By Age, Both Sexes, N (Row %), 2012 74
Table 15: 10MM, Prevalent Cases of UC, By Sex, Ages =10 Years, N (Row %), 2012 76
Table 16: Truelove and Witts UC Severity Index 83
Table 17: UCDAI 84
Table 18: Treatment Guidelines for UC Used in the 10MM 85
Table 19: Most Commonly Prescribed Drugs for UC by Class in the 10MM, 2013 86
Table 20: UC Management Country Profile US 92
Table 21: UC Management Country Profile France 94
Table 22: UC Management Country Profile Germany 97
Table 23: UC Management Country Profile Italy 100
Table 24: UC Management Country Profile Spain 102
Table 25: UC Management Country Profile UK 105
Table 26: UC Management Country Profile Japan 107
Table 27: Country Profile Canada 110
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/

3. Table 28: UC Management Country Profile China 112
Table 29: UC Management Country Profile India 115
Table 30: Leading Treatments for UC, 2014 118
Table 31: Product Profile Remicade 121
Table 32: Remicade SWOT Analysis, 2014 125
Table 33: Global Sales Forecasts ($m) for Remicade, 20122022 126
Table 34: Product Profile Humira 128
Table 35: Humira Efficacy in the ULTRA 2 Trial 129
Table 36: Product Efficacy Comparison Humira vs. Remicade 129
Table 37: Humira SWOT Analysis, 2014 131
Table 38: Global Sales Forecasts ($m) for Humira, 20122022 132
Table 39: Product Profile Simponi 134
Table 40: Simponi SWOT Analysis, 2014 136
Table 41: Global Sales Forecasts ($m) for Simponi, 20122022 137
Table 42: Product Profile Apriso 139
Table 43: Apriso SWOT Analysis, 2014 141
Table 44: Global Sales Forecasts ($m) for Apriso, 20122022 142
Table 45: Product Profile Asacol HD 144
Table 46: Asacol HD SWOT Analysis, 2014 147
Table 47: Global Sales Forecasts ($m) for Asacol HD, 20122022 148
Table 48: Product Profile Lialda 149
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/

4. Table 49: Lialda SWOT Analysis, 2014 151
Table 50: Global Sales Forecasts ($m) for Lialda, 20122022 152
Table 51: Product Profile Pentasa 153
Table 52: Pentasa SWOT Analysis, 2014 155
Table 53: Global Sales Forecasts ($m) for Pentasa, 20122022 156
Table 54: Product Profile Colazal 157
Table 55: Colazal SWOT Analysis, 2014 159
Table 56: Global Sales Forecasts ($m) for Colazal, 20122022 160
Table 57: Product Profile Giazo 161
Table 58: Giazo SWOT Analysis, 2014 163
Table 59: Global Sales Forecasts ($m) for Giazo, 20122022 164
Table 60: Product Profile sfRowasa 165
Table 61: sfRowasa SWOT Analysis, 2014 166
Table 62: Global Sales Forecasts ($m) for sfRowasa, 20122022 167
Table 63: Product Profile Uceris 168
Table 64: Uceris SWOT Analysis, 2014 170
Table 65: Global Sales Forecasts ($m) for Uceris, 20122022 171
Table 66: Summary of Other Immunomodulators for UC, 2013 172
Table 67: Biosimilars Pipeline, 2013 174
Table 68: Global Sales Forecasts ($m) for Infliximab Biosimilars, 20122022 177
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/

5. Table 69: Global Sales Forecasts ($m) for Adalimumab Biosimilars, 20122022 177
Table 70: Global Sales Forecasts ($m) for Golimumab Biosimilars, 20122022 178
Table 71: Overall Unmet Needs Current Level of Attainment 179
Table 72: Corticosteroid Long-Term Side Effects 182
Table 73: Clinical Unmet Needs in UC Gap Analysis, 2013 185
Table 74: Prognostic Markers in UC 186
Table 75: UC Clinical Trials by Phase and Status, 2014 189
Table 76: UC Pre-Registration and Phase III Pipeline, 2014 189
Table 77: Comparison of Therapeutic Classes in Development for UC, 2014 190
Table 78: Product Profile Entyvio 193
Table 79: Results of the GEMINI I Trial, Efficacy of Vedolizumab in the Induction of Remission in UC 194
Table 80: Results of the GEMINI I Trial, Efficacy of Vedolizumab in the Maintenance of Remission in UC
195
Table 81: Most Common Adverse Events with Vedolizumab in the GEMINI I Study 196
Table 82: Entyvio SWOT Analysis, 2014 199
Table 83: Global Sales Forecasts ($m) for Entyvio, 20122022 201
Table 84: Product Profile Xeljanz 202
Table 85: Results of Phase IIa Trial of Xeljanz in the Induction of Remission in UC 203
Table 86: Most Common Adverse Events in the Phase IIa Trial of Xeljanz 205
Table 87: Xeljanz SWOT Analysis, 2014 207
Table 88: Global Sales Forecasts ($m) for Xeljanz, 20122022 208
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/

6. Table 89: Product Profile Kappaproct 209
Table 90: Results of Phase IIb Trial of Kappaproct in the Induction of Remission in UC 210
Table 91: Kappaproct SWOT Analysis, 2014 212
Table 92: Global Sales Forecasts ($m) for Kappaproct, 20122022 213
Table 93: Key Companies in the UC Market, 20122022 215
Table 94: J&Js UC Portfolio Assessment, 2014 221
Table 95: J&Js SWOT Analysis in UC, 2014 222
Table 96: AbbVies UC Portfolio Assessment, 2014 223
Table 97: AbbVies UC SWOT Analysis, 2014 224
Table 98: Takeda Pharmaceuticals UC Portfolio Assessment, 2014 225
Companies in Report:
 J&J
 AbbVie
 Takeda
 Warner Chilcott
 Salix/Santarus
 Shire
 Ferring
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/

7.  Pfizer
 InDeX Pharmaceuticals
About JSB Market Research:JSB market research is a leading player in the market of research report distribution. It is
one-stop-shop for all information related to market research for any sector of the industry.
Along with providing in-depth analysis though reports, JSB market research also provides
regular updates of the market though newsletters. Our reports are a well-researched work
of market researchers with an extensive knowledge and a good level of market experience.
To understand more on the PharmaPoint: Ulcerative Colitis read the modern research reports on
http://www.jsbmarketresearch.com/healthcare-medical/r-PharmaPoint-Ulcerative-ColitisGlobal-Drug-Forecast-and-Market-Analysis-to-2022-89051
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/

8. Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/